A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
Authors:
- Giovanni MarascoGiovanni Marasco
- Francesco PoggioliFPFrancesco Poggioli
- Antonio ColecchiaAntonio Colecchia
- Giuseppe CabibboGiuseppe Cabibbo
- Filippo PelizzaroFPFilippo Pelizzaro
- Edoardo Giovanni GianniniEdoardo Giovanni Giannini
- Sara MarinelliSMSara Marinelli
- Gian Ludovico RapacciniGRGian Ludovico Rapaccini
- Eugenio CaturelliECEugenio Caturelli
- Mariella Di MarcoMMMariella Di Marco
- Elisabetta BiasiniEBElisabetta Biasini
- Fabio MarraFMFabio Marra
Open Access
Abstract
Among scores and staging systems used for HCC, none showed a good prognostic ability in patients with advanced HCC treated with Sorafenib. We aimed to evaluate predictive factors of overall survival (OS) and drug response in HCC patients undergoing Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Patients in the ITA.LI.CA database treated with Sorafenib and updated on 30 June 2019 were included. Demographic and clinical data before starting Sorafenib treatment were considered. For the evaluation of predictive factors for OS, a time-dependent Cox proportional hazard model was used. A total of 1107 patients were included in our analysis. The mean age was 64.3 years and 81.7% were male. Most patients were staged as BCLC B (205, 18.9%) or C (706, 65.1%). The median time of Sorafenib administration was 4 months (interquartile range (IQR) 2–12), and the median OS was 10 months (IQR: 4–20). A total of 263 patients (33.8%) out of 780 with available evaluation experienced objective tumoral response to Sorafenib. The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (hazard ratio (HR) 1.284), maximum tumoral diameter (HR 1.100), plasma total bilirubin (HR 1.119), aspartate amino transferase assessed as multiple of the upper normal value (HR 1.032), alpha-fetoprotein ≥200 ng/mL (HR 1.342), hemoglobin (HR 0.903) and platelet count (HR 1.002) were associated with OS at multivariate Cox regression analysis. Drug response was predicted by maximum tumoral diameter and platelet count. A novel prognostic nomogram for patients undergoing Sorafenib is hereby proposed. The novelty introduced is the comprehensive patient’s assessment using common markers of patient’s general status, liver damage and function and HCC biology. Further studies are required to test its accuracy and provide external validation.Keywords
This publication has 65 references indexed in Scilit:
- Clinical parameters predictive of outcomes in sorafenib‐treated patients with advanced hepatocellular carcinomaLiver International, 2013
- Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinomaHepatology, 2013
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular CarcinomaOncology, 2011
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving SorafenibThe Oncologist, 2011
- Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic ModelsOncology, 2011
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with SorafenibThe Oncologist, 2010
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- Spectrum of anemia associated with chronic liver diseaseWorld Journal of Gastroenterology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trialsAnnals of Oncology, 2008